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As I reported, the phase II trial shows that,
depending on the subgroup, patients with in-
operable pancreatic cancer have a threefold to
sixfold dose related improvement in survival.
None of the common toxic effects of chemotherapy
for cancer were observed. These dose related
effects, the investigators report, are "relatively
robust with high degrees of statistical significance."
This work seemed to be of great interest, partly
because there are no effective treatments for
pancreatic cancer and partly because of the lack
of toxicity of lithium gammalinolenate given intra-
venously over two weeks. Readers of the Times
were aware of this work, even if Petrie was not.
Petrie complains that the article gives the im-
pression that the treatment is a simple dietary
supplement. This is not stated or implied anywhere
in the article. Lithium gammalinolenate has now
been given to around 150 patients with otherwise
untreatable cancers. More than 70 people who, like
Petrie, approached Scotia Pharmaceuticals for
information have been offered full information on
the drug and, when appropriate, supplies of
it on compassionate grounds. With the exception
of Petrie, all seem to have appreciated the in-
formation.
Medical journalists have a tricky task in balanc-
ing hope against discouragement. Many hopeful
stories are published when no studies other than
those in the laboratory or in animals have been
completed. I need make no apology for reporting
on lithium gammalinolenate, given the completed
phase II trials, the start of phase III trials, and the
low toxicity of the drug-a rare combination.
NIGELHAWYKES
Science editor
Times,
London El 9XN
1 Petrie JR. The cruelty of false hope. BMJ 1994;308:1723.
(25 June.)
Fatty acids for treating
pancreatic cancer
ED1TOR,-John R Petrie has expressed his concern
over the overstatement by the Times of the thera-
peutic role of essential fatty acids in the treatment
of pancreatic cancer. Although we share his
opinion, we would like to make it clear that they
do have a potential role in the treatment of
advanced pancreatic cancer based on sound scien-
tific evidence. The interest in both gammalinolenic
acid and eicosapentaenoic acid lies in their possible
palliative role as anti-cachexia agents. Pancreatic
cancer is often associated with profound weight
loss, which in turn is associated with increased
morbidity and mortality. This weight loss cannot
be explained solely by reduced nutritional intake
and has been associated with a persistent activation
of the hepatic acute phase response and raised
resting energy expenditure.'
The hypothesis underlying the use of these fatty
acids as anti-inflammatory drugs derives from their
effects on altering prostaglandin synthesis. They
compete with arachidonic acid for the cyclo-
oxygenase and lipooxygenase enzymes and divert
prostaglandin production away from the 2 series
toward the 3 series (eicosapentaenoic acid) and 1
series (gammalinolenic acid).3 This alteration of
prostaglandin synthesis seems to be associated
with abrogation of the inflammatory response. The
fatty acids have been shown to reduce weight
loss significantly in animal cancer models.4 The
potential to downregulate the hepatic acute phase
response and energy expenditure with fatty acids
might increase survival in pancreatic cancer
patients who are losing weight. We make the experi-
mental nature of these drugs quite clear to our
patients, and, although there is some evidence of
in vitro tumour cell killing,5 we emphasise that we
consider these treatments to be palliative anti-
cachexia agents. It should also be mentioned that
the toxicity profiles of both drugs are significantly
better than those associated with conventional
chemotherapy, which is an important considera-
tion in patients who have a limited life expectancy.
The overstatement of medical data in the press
may serve to undermine the confidence of patients
and ofpractitioners responsible for their care.
STEPHENJWIGMORE
Wilkie research fellow
JSTUARTFALCONER
Registrar
KENNETH C H FEARON
Senior lecturer
Department of Surgery,
University ofEdinburgh,
Royal Infirmary,
Edinburgh EH3 9YW
1 Petrie JR. The cruelty of false hope. BMJ 1994;308:1723. (25
June.)
2 Falconer JS, Fearon KCH, Plester CE, Ross JA, Carter DC.
Cytokines, the acute phase response and energy expenditure in
weight-losing patients with pancreatic cancer. Ann Surg 1994;
219:325-31.
3 Powell WS, Gravelle F. Metabolism of eicosapentaenoic acid by
aorta: formation of a novel 13-hydroxylatedprostaglandin.
Biochim BiophysActa 1985;835:201-1 1.
4 Beck SA, Smith KL, Tisdale MJ. Anticachetic and antitumour
effect of eicosapentaenoic acid and its effect on protein
turnover. Cancer Res 1991;51:6089-93.
5 Falconer JS, Ross JA, Fearon KCH, Hawkins RA, O'Riordan
MG, Carter DC. Effect ofeicosapentaenoic acid and other fatty
acids on the growth in vitro of human pancreatic cancer cell
lines. BrJ Cancer 1994;69:826-32.
Informal complaints procedure
in general pracdce
ED1TOR,-P C Pietroni and S de Uray-Ura's paper
reporting their experience of an informal com-
plaints procedure in general practice raises several
issues.' Firstly, a patient liaison worker was chosen
to handle the complaints, and this person may have
been viewed as a member of the practice team. The
patients may have wondered whether complaints
would be resolved impartially.
Secondly, although the paper records the
outcomes of the complaints, it does not mention
the degree of satisfaction felt by the patients. The
end point of the complaints procedure was decided
by the patient liaison worker, not by the patients.
Thirdly, although complaints by staff were
addressed, no explanation is given about what
action could be taken if the member of staffwas not
satisfied with the outcome. Being able to air a
grievance is often of therapeutic value, but if
no positive steps can be taken it may lead to
disillusionment with the procedure.
Fourthly, the cost implications of introducing
the procedure are reported as having been minimal,
but there is no evidence to show this in the article. I
wonder whether it would be so easy to set up such
a procedure in an already overstretched general
practice.
Finally, I am concerned to see such a large rise in
the number of complaints compared with previous
years. Were these complaints made for the sake of
complaining or were they genuine? I also wonder
whether the cumulative effect (on stress levels and
morale) of several small complaints dealt with at
local level exceeds the effect caused by far fewer
complaints that take longer to resolve. Although
we must all persevere to provide a better service to
our patients, I believe that we should not encourage
complaints or forget our own wellbeing in trying to
provide this service.
V S SAMARATUNGA
Trainee general practitioner
Chalgrove,
Oxfordshire OX44 7SR
1 Pietroni PC, de Uray-Ura S. Informal complaints procedure in
general practice: first year's experience. BMJ 1994;308:
1546-8. (11 June.)
Airline's magazine promotes
production oftobacco
products
EDITOR,-During a recent British Airways flight
we were appalled to read, in the company's Business
Life magazine, an article celebrating the profits to be
made from producing tobacco products in eastem
Europe.' The article described in glowing terms
how one entrepreneur had negotiated a licence to
produce tobacco products in an eastern European
country and, through careful tax planning, had
enabled profits to be brought back to western
Europe.
Perhaps British Airways is not aware that
mortality and morbidity in eastern Europe are
increasing and that one of the main reasons for this
is the increase in cigarette smoking. Furthermore,
health care services in the new democracies have
been severely weakened by reduced tax receipts,
and this has contributed to the increase in mor-
tality.' The ethics of encouraging the production of
tobacco products and (albeit legal) minimising of
tax are therefore dubious. We expect better from
"the world's favourite airline."
NAOMIJ FULOP
Senior research fellow
MARTINMcKEE
Senior lecturer
Department ofPublic Health and Policy,
Health Services Research Unit,
London School ofHygiene and Tropical Medicine,
London WC1E 7HT
1 Shane I. Europe's wild frontier. Business Life 1994 June:40-4.
2 Unicef. Public policy and sodal conditions. Florence: Unicef
Intemational Child Development Centre, 1993. (Regional
monitoring report No 1.)
British Airways' response
EDrrOR,-Neither British Airways nor its pub-
lishers, Premier Magazines, had any intention of
condoning cigarette smoking in eastem Europe or
encouraging tax evasion. The point of the article,
which was written by a well known tax lawyer, was
to reveal to interested businessmen and business-
women the pitfalls that exist for newcomers to this
area of tumultuous change. In writing about the
entrepreneur who dealt in tobacco products the
author merely wanted to give readers an indication
of business dealings in a market very different from
that of westem Europe. The practice of dealing
in tobacco products was neither condoned nor
encouraged, but to pretend that such practice does
not exist would be to ignore an undeniable fact of
eastern Europen life.
Business Life's brief is to give its readers an
accurate and informed view of what is happening
in European business, in both the East and the
West, and to offer guidance when possible. The
article included not only a six point guide on how to
conduct business effectively and legally while
keeping an eye out for local customs but a further
reference to major sources of reliable business
information on central and eastern Europe.
PETERJONES
Head ofpublic relations
British Airways,
PO Box 10,
Heathrow Airport (London),
HounslowTW6 2JA
Correction
Doctors should supervise administration of
methadone
An editorial error occurred in this letter by P D
Thomas (2 July, pp 534). The last line of the letter
should read, "It now seems that pharmacists in
maintenance programmes have far more to offer than
doctors concemed, so perhaps we will soon hear ofthe
deregulation of methadone to pharmacy list status."
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